Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Harbinger Health
Age
20–79
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Subjects must meet the following criteria in order to be included in the research study:
Written or electronic informed consent
Subject is 20 - 79 years of age at the time of signature of the informed consent form (ICF)
Male or female subjects
A confirmed diagnosis or high suspicion of cancer (stage I to IV solid cancer or hematologic cancer) by imaging within 180 days prior to enrollment; not to include myelodysplastic and myeloproliferative syndromes
Subject's cancer diagnosis is based upon assessment of a pathological specimen or high suspicion of cancer by imaging
Subject's cancer is treatment-naïve
Subject's health permits participation and the subject is not suspected of having cancer based on provider assessment.
The subject was not diagnosed with cancer or received cancer treatment within the last 5 years (persons with completely resected ductal carcinoma in-situ or non-melanoma skin cancer are permitted).
Part 1B Only :
\- Subject has no known current cancer and has 1 of the follow conditions:
o An Advanced Adenoma (AA) of the gastrointestinal tract as defined as an adenoma that is ≤10mm in size Subjects with any one of the criteria would be eligible High grade displasia or ≥10 adenoma: any size Tubulovillous adenoma, any size Tubular adenoma ≥10mm Traditional serrated adenoma ≥10mm
You may not be if
Subjects who meet any of the following criteria will be excluded from study entry:
Subject is suffering from any febrile illness defined as a temperature \>101.5°F within the last 48 hrs.
Subject is pregnant (by self-report of pregnancy status).
Subjects who meet any of the following criteria will be excluded from study entry:
Subject with a prior history of cancer within 5 years will not be allowed to participate in the study
More than 1 active cancer diagnosis (ie. a subject presenting with recurrent breast cancer and newly diagnosed lung cancer would be excluded; subject with prior (\>5 years ago) treated breast cancer without recurrence and presenting with newly diagnosed lung cancer would be eligible).
Subject is currently receiving, or has in the past received, any of the following definitive therapies to treat their current cancer:
* Surgical treatment, surgical removal, or surgical management of the cancer beyond that required to establish the cancer diagnosis. Surgical or biopsy procedures that remove more tissue than required to establish the cancer diagnosis, or that were performed to manage symptoms or initiate cancer treatment prior to blood sample collection will be considered 'definitive' and are not permissible regardless of the residual tumor mass remaining in the subject.
* Chemotherapy (local, regional, or systemic) including chemoembolization targeted therapy;
* Immunotherapy including cancer vaccines;
* Hormone therapy; or
* Radiation therapy (a single dose of palliative radiation prior to study start is allowed).
The subject is a recipient of an organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant.
Subject who has undergone a bowel preparation for a gastrointestinal malignancy within 3 days of an anticipated blood draw.
Subjects who meet any of the following criteria will be excluded from study entry:
\- The subject is the recipient of an organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant.
Clareo Health | Development and Validation of Harbinger Health Test for Early Cancer Detection
